For Patients With a Positive Sentinel Node in Breast Cancer, Radiotherapy is Comparable to Dissection
the Cancer Therapy Advisor take:
According to a new study published in the journal The Lancet Oncology, dissection and radiotherapy of the axillary lymph node following a positive sentinel node are effective approaches for proving axillary control in patients with T1-2 primary breast cancer without palpable lymphadenopathy.
For the randomized, multicenter, open-label, phase 3 non-inferiority AMAROS study, researchers randomly assigned 4,806 patients to receive axillary lymph node dissection, the current standard of care, or axillary radiotherapy. Patients with positive sentinel lymph nodes were followed for a median of 6.1 years.
Of the 744 patients with a positive sentinel node in the axillary lymph node dissection group, four patients experienced axillary recurrence compared with seven of 681 patients with a positive sentinel node in the axillary radiotherapy group. Results showed a 5-year axillary recurrence rate of 0.43% (95% CI, 0.00 - 0.92) in the dissection group compared with 1.19% (95% CI, 0.31-2.08) in the radiotherapy group.
Axillary lymph node dissection was more often associated with lymphoedema in the ipsilateral arm versus axillary radiotherapy after 1, 3, and 5 years. The findings suggest that axillary radiotherapy provides equivalent regional control with fewer adverse effects versus axillary lymph node dissection.
Radiotherapy of the axillary lymph node following a positive sentinel node effective approach.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro
- Age-adjusted Comorbidity Predicts Survival in Laryngeal Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Role of miR-125a-5p Clarified in Bladder Cancer